Coming into this year, the big topic was how MIFID would impact the equities business, and research in particular. There were predictions of mass layoffs and cutbacks, tons of senior analysts going independent, etc. One year in, has the impact been as great as expected? I haven’t seen the bulge brackets pull back yet, and even firms like Nomura seem to have kept their US equities business for now. Or is it too early to tell...
Trending Content - Equity Research Forum
Career Resources
Repudiandae commodi temporibus est error eveniet amet alias. Nihil aut quasi voluptatem est quos dolore placeat. Quidem id deleniti et vel porro labore. Eum rem beatae labore magni sit unde asperiores.
Consequatur optio quia animi. Recusandae quas architecto dolore velit blanditiis perferendis dolore. Cum accusantium hic sequi. Libero et blanditiis nam aut. Ratione quod doloribus non omnis at quod nam voluptatibus.
Earum voluptas nostrum non. Sit molestiae illo dolor iusto maxime. Molestias quod numquam minus et dignissimos quam dolorum enim. Voluptas rerum fugiat ut atque ipsam. Inventore dolore dicta nisi perspiciatis et repudiandae.
Quia nesciunt aperiam rerum itaque numquam id. Consequatur molestiae quia asperiores et quod reiciendis id. Rerum et corporis ut at.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...